Core Insights - Envoy Medical has received FDA approval to expand its pivotal clinical trial for the fully implanted Acclaim® Cochlear Implant to its final stage, marking a significant milestone for the company [1][2] - The company has strengthened its balance sheet by extinguishing $32 million in debt, which positions it for future growth [3][4] - A transformational capital raise was completed in February 2026, involving established institutional healthcare investors, which will support ongoing clinical trials and future product development [4][5] Financial Performance - For the year ended December 31, 2025, net revenue increased to $241,000 from $225,000 in 2024, primarily driven by sales of the Esteem® FI-AMEI implant and related components [5][21] - Cost of goods sold rose to $874,000, up from $742,000 in 2024, largely due to increased scrap and non-recurring expenses [6][21] - Research and development expenses surged by $2,307,000 to $12,486,000, reflecting additional costs associated with the Acclaim pivotal clinical trial [7][21] - Sales and marketing expenses decreased to $1,220,000 from $1,734,000, attributed to reduced legal fees related to reimbursement work for the Esteem product [8][21] - General and administrative expenses increased by $1,105,000 to $7,931,000, mainly due to severance costs and higher consulting expenses [9][21] Balance Sheet Overview - As of December 31, 2025, total assets were approximately $8.56 million, down from $11.54 million in 2024 [19][20] - Current liabilities increased to $11.56 million from $7.54 million, reflecting higher accounts payable and accrued expenses [20] - The company's stockholders' deficit improved to $(12.16 million) from $(18.84 million) in 2024, indicating a stronger financial position [20] Future Outlook - The company aims to revolutionize hearing health with fully implanted solutions, addressing the needs of millions with severe to profound sensorineural hearing loss [4][5][12] - The Acclaim cochlear implant, which received Breakthrough Device Designation from the FDA in 2019, is expected to be a key product in the company's portfolio [10][13]

Core Insights - Envoy Medical has completed enrollment for its pivotal clinical trial of the fully implanted Acclaim® cochlear implant, marking a significant milestone as the first cochlear implant company to achieve this in the U.S. [1][4] Company Overview - Envoy Medical, listed on NASDAQ as COCH, specializes in innovative hearing health technologies, including fully implanted devices for hearing loss [6]. - The company has previously launched the Esteem® active middle ear implant, which has been commercially available since 2010 [6]. Clinical Trial Details - The pivotal trial for the Acclaim cochlear implant received Breakthrough Device Designation from the FDA in 2019 and is currently under investigation [4][8]. - The trial involved 56 participants, with the final two patients implanted by Dr. Patrick Antonelli at the University of Florida [2][3]. - Following the completion of enrollment, the study will proceed with follow-up visits and data collection, with a PMA application to be submitted to the FDA after 12 months of data collection [3]. Product Features - The Acclaim cochlear implant is designed for adults with severe to profound sensorineural hearing loss and aims to provide a fully implanted solution without the need for an external processor [7][8]. - The device utilizes a sensor that leverages the natural anatomy of the ear to capture sound, representing a significant advancement over traditional cochlear implants [7].

Core Viewpoint - Envoy Medical has announced the issuance of three new patents, enhancing its intellectual property and competitive position in the cochlear implant industry [1][2]. Patent Issuance - The United States Patent and Trademark Office granted U.S. Patent No. 12,544,564, which focuses on improving the input signal-to-noise ratio in cochlear implant systems [3]. - Two patents were granted in Hong Kong: - HK40102155 relates to a combination hearing aid and cochlear implant system that updates the signal processor based on the status of an external auditory aid [4]. - HK40107235 pertains to electrode impedance diagnostics within cochlear implant systems, allowing for the determination of stimulation parameters based on impedance [5]. Company Strategy and Market Position - The CEO of Envoy Medical emphasized the company's belief in the future of fully implanted devices, highlighting the uniqueness of their approach compared to existing designs [2]. - The strength of the intellectual property portfolio is seen as a strategic asset as the company moves towards potential Premarket Approval (PMA) submission and commercialization [2]. Product Development - The Acclaim® cochlear implant received Breakthrough Device Designation from the FDA in 2019 and is currently undergoing a pivotal clinical trial in the U.S. [6]. - The Acclaim CI is designed for individuals with severe to profound sensorineural hearing loss and aims to leverage the natural anatomy of the ear for sound capture [9][8]. Company Overview - Envoy Medical is focused on innovative technologies for hearing loss, having developed fully implanted devices like the Esteem® active middle ear implant and the investigational Acclaim® cochlear implant [7].

Core Viewpoint - Envoy Medical has successfully closed a public offering, raising approximately $30 million, with potential additional proceeds of up to $48 million from milestone-linked warrants, which reflects strong investor confidence in the company's cochlear implant technology [1][2][4]. Financial Details - The offering consisted of 75 million shares of Class A common stock at a price of $0.40 per share, along with Series A-1 and Series A-2 common warrants [1][4]. - The net proceeds from the offering are expected to extend the company's cash runway into the second half of 2027, beyond the anticipated submission of the Premarket Approval (PMA) application [2][5]. Warrant Information - Series A-1 common warrants have an exercise price of $0.40 per share and will expire 24 months after stockholder approval or 30 days after the PMA submission announcement [3]. - Series A-2 common warrants also have an exercise price of $0.40 per share, expiring 60 months after stockholder approval or 30 days after FDA approval announcement [3]. Use of Proceeds - The company plans to utilize the net proceeds for working capital and general corporate purposes, particularly to fund operations during its FDA pivotal clinical study [5]. Company Overview - Envoy Medical is focused on innovative hearing health technologies, including the fully implanted Acclaim cochlear implant, which is currently investigational [8].

Core Viewpoint - Envoy Medical, a hearing health company, is set to participate in the Small Cap Growth Virtual Investor Conference on February 5, 2026, highlighting its commitment to innovation in hearing solutions [1]. Group 1: Company Overview - Envoy Medical (NASDAQ: COCH) specializes in innovative technologies for hearing loss, offering fully implanted devices such as the Esteem® active middle ear implant, available in the U.S. since 2010, and the investigational Acclaim® cochlear implant [2]. Group 2: Event Details - The Small Cap Growth Virtual Investor Conference will take place on February 5, 2026, at 10:00 A.M. ET, featuring a presentation followed by a real-time Q&A session for investors [1]. - A recording of the event will be accessible on Envoy's Investor Relations website for those unable to attend the live session [1].

As filed with the U.S. Securities and Exchange Commission on December 18, 2025. Registration No. 333- (State or other jurisdiction of incorporation or organization) FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Primary Standard Industrial Classification Code Number) Delaware 3842 86-1369123 (IRS Employer Identification Number) 4875 White Bear ...

Core Insights - Envoy Medical will host a fireside chat featuring CEO Brent Lucas and Craig Eggert, the first patient to receive the Acclaim cochlear implant, on December 11, 2025, at 4:30 P.M. ET [1][2] Company Overview - Envoy Medical, listed on NASDAQ as COCH, is a hearing health company focused on innovative technologies for hearing loss, including fully implanted devices like the Esteem active middle ear implant and the investigational Acclaim cochlear implant [3][4] - The Acclaim cochlear implant is designed to address severe to profound sensorineural hearing loss and has received Breakthrough Device Designation from the FDA in 2019 [5] Product Details - The Acclaim cochlear implant utilizes a sensor that leverages the natural anatomy of the ear to capture sound, distinguishing it as a first-of-its-kind hearing device [4] - The Esteem fully implanted active middle ear implant is the only FDA-approved device for adults with moderate to severe sensorineural hearing loss, providing continuous hearing without the need for external components [7]

As filed with the U.S. Securities and Exchange Commission on December 1, 2025. Registration No. 333-290927 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 3842 86-1369123 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (IRS Employer Identification ...

As filed with the U.S. Securities and Exchange Commission on December 1, 2025. Registration No. 333-290927 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) Delaware 3842 86-1369123 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (IRS Employer Identification ...

Core Insights - Envoy Medical experienced a transformational third quarter in 2025, significantly improving its financial position by eliminating $32 million in debt and strengthening its balance sheet [2][5][6] - The company received FDA approval to expand its pivotal clinical trial to the final stage, which is expected to enhance its market position in fully implanted hearing solutions [2][8] - Envoy Medical's net revenue for the third quarter was $42 thousand, a decrease from $56 thousand in the same period of 2024 [5][17] Financial Highlights - Research and Development (R&D) expenses decreased by $57 thousand to $2.7 million compared to the same quarter in 2024, as the company transitioned from development to clinical trial phases [5][17] - General and administrative expenses increased by $752 thousand, primarily due to public company costs and expenses related to a September 2025 offering [5][17] - As of September 30, 2025, the company had approximately $3.556 million in cash, down from $5.483 million at the end of 2024 [6][15] Operational Developments - The company continued to receive additional global patents in the U.S., Europe, and Australia, reinforcing its position as a market leader in fully implanted hearing solutions [2][7] - The Acclaim Cochlear Implant, an investigational device, is designed to address severe to profound sensorineural hearing loss and has received Breakthrough Device Designation from the FDA [8][9] Market Position - Envoy Medical aims to capitalize on its first-mover advantage in the fully implanted hearing solutions market, with ongoing interest in its cochlear implant trial [2][8] - The company is dedicated to advancing hearing technology to improve access and quality of life for individuals with hearing loss [7][8]